Patients Peptide vaccine Adjuvant Response Ref. 10 resected and 38 advanced pancreatic caner Mutant K-ras peptide GM-CSF Immune response to the peptide vaccine showed prolonged survival compared to nonresponders.
[56 ] K-ras-specific T cells were selectively accumulated in the tumor. 24 resected pancreatic cancer Mutant K-ras peptide GM-CSF No elicitable immunogenicity and unproven efficacy was observed. [57 ] 16 resected or locally advanced pancreatic cancer 100 mer MUC1 peptide SB-AS2 adjuvant Detectable MUC1-specific humoral and T-cell responses were detected in some patients. [59 ] 6 advanced pancreatic cancer 100 mer MUC1 peptide Incomplete Freund's adjuvant One patient showed a tendency for increased circulating anti-MUC1 IgG antibody. [58 ] 48 advanced pancreatic cancer Telomerase peptide GM-CSF Immune responses were observed in 24 of 38 evaluable patients.
[60 ] One-year survival for the evaluable patients in the intermediate dose group was 25%. 11 advanced pancreatic cance Personalized peptide vaccine The 6- and 12-month survival rates for patients who received >3 vaccinations (
) were 80% and 20%, respectively. [62 ] 23 resected pancreatic cancer Mutant ras long peptide Seventeen of 20 evaluable patients (85%) responded immunologically to the vaccine.
[65 ] Ten-year survival was 20% (four patients out of 20 evaluable). 1 liver metastasis of pancreatic cancer refractory to gemcitabine Survivin peptide The patient initially underwent partial remission of liver metastasis which proceeded after 6 months into a complete remission with a duration of 8 months. [40 ]
